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Summary To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further
trials of docetaxel in combination with a 5-day continuous infusion of 5-fluorouracil (5-FU) in advanced or recurrent breast cancer patients who
had been treated previously with at least one chemotherapeutic regimen, patients were treated with docetaxel as a 1-h infusion on day 1
followed by 5-FU as a continuous infusion on days 1 through 5 every 3-4 weeks. Three or six patients were assessed at the following
escalating dose levels of docetaxel/5-FU per day: 40/150, 40/300, 50/300, 50/500 and 60/500 mg m-2. Nineteen patients entered this trial, of
whom 18 could be assessed for adverse event and therapeutic efficacy. The DLTs were neutropenia and diarrhoea. The MTDs were
60 mg m-2 of docetaxel on day 1 and 500 mg m-2 per day of 5-day continuous infusion of 5-FU. One of 18 patients achieved a complete
response and eight achieved partial response (over all response rate: 50%). The recommended doses of docetaxel and 5-day continuous
infusion of 5-FU for a phase 11 trial are 50 mg m-2 and 500 mg m-2 per day every 3 or 4 weeks.
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Chemotherapy for advanced or recurrent breast cancer is pallia-
tive, not curative, in intent. The objective response rates to stan-
dard chemotherapeutic regimens in previously untreated patients
with metastatic breast cancer (MBC) have been reported to be
45-80%, with median duration of response of 5-13 months and
median duration of survival of 15-33 months (DeVita et al, 1993).
Relief of symptoms and improvement of quality of life can be
achieved using these standard regimens but survival benefit has
not been clearly demonstrated. It has been reported that the
response rate to second-line chemotherapies was 16%, less than
that to first-line chemotherapy (Gregory et al, 1993). Thus, the
search for more effective salvage treatment regimens with durable
response for MBC patients has been a major clinical research
priority.
Docetaxel [Taxotere (Rhone-Poulenc Rorer, Collegevile, PA,
USA), N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl taxol, RP
56976] is a semisynthetic taxane that is prepared from a non-cyto-
toxic precursor extracted from needles of European yew trees
(Lavelle et al, 1995). In phase II trials that were conducted in
Europe, Canada and the USA, docetaxel was administered at a
dose of 100 mg m-2 over 1 h every 3 weeks. The objective response
rates were between 57% and 68% in patients with previously
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untreated MBC (Trudeau et al, 1993; Chevallier et al, 1995; Hudis
et al, 1996). In Japanese phase II trials, docetaxel was administered
at a dose of 60 mg m-2 over 1 h every 3 or 4 weeks, a dosage and
schedule based on a phase I trial conducted in Japan (Taguchi et al,
1994a). Objective response rates in patients with previously
treated MBC were 44.4% and 54.7% (Adachi et al, 1996; Taguchi
et al, 1994b). In some phase II trials, response rates to docetaxel at
a dose of 100 mg m-2 over 1 h every 3 weeks in patients with
anthracycline-resistant MBC were 53% and 57% (Valero et al,
1995; Ravdin et al, 1995). The median response durations for
responders were 7.5 and 4 months respectively. Thus, many
clinicians have high expectations for docetaxel as a second-line
chemotherapy for MBC.
In the treatment of breast cancer, 5-fluorouracil (5-FU) is a
common agent of fluorinated pyrimidines (Ansfield et al, 1969).
Response rates of 25-35% have been reported in the treatment of
MBC using a single-agent bolus injection. For patients with previ-
ously treated breast cancer, the overall response rate ofcontinuous
5-FU infusions as a single agent is about 30% in the various
published series (Jabboury et al, 1989; Cameron et al, 1994).
It has been reported that the combination of docetaxel and 5-FU
showed a synergistic effect in mouse tumour models (Bissery et al,
1993). Therefore, we conducted a phase I study ofa combination of
docetaxel and 5-FU in the treatment ofadvanced or recurrent breast
cancer. The aims ofthis study were (1) to determine the maximum-
tolerated dose (MTD) and recommended dose of docetaxel and
5-FU administered as a 5-day continuous intravenous infusion, (2)
to qualify and quantify adverse events of this combination and (3)
to observe the therapeutic efficacy ofthis regimen.
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PATIENTS AND METHODS
All of the patients were treated at the National Cancer Center
Hospital or National Cancer Center Hospital East. The protocol
was approved by the Institutional Review Board of the National
Cancer Center.
Eligibility
Eligibility criteria were as follows: (1) histologically or cytologi-
cally documented breast cancer and histologically, cytologically or
clinically proven metastatic or recurrent breast cancer; (2) measur-
able or evaluable disease; (3) prior chemotherapy (patients must
have received at least one chemotherapeutic regimen for either adju-
vant or metastatic disease but not more than one prior chemothera-
peutic regimen for recurrence in addition to any prior adjuvant
chemotherapy); (4) prior cumulative doxorubicin dose less than
560 mg m-2; (5) recovery from all side-effects of prior therapies,
more than 4 weeks after completion of prior chemotherapy and
more than 2 weeks after completion ofendocrine therapy or irradia-
tion for extra-evaluable site of disease; (6) an Eastern Cooperative
Oncology Group (ECOG) performance status of 0-2; (7) life
expectancy greater than 3 months; (8) adequate organ function
[white blood cell (WBC) count 4000 1-, < 10 000 ,tl-', absolute
neutrophil count 2000 p-', platelet count 100 000 .tl-', haemo-
globin 9.5 g dl-', transaminases level without liver metastases
< 2.5 times upper normal limit or with liver metastases < 3 times
upper normal limit, total bilirubin < 1.5 mg dl-', serum albumin
> 3.0 g dl-', serum creatinine and blood urea nitrogen (BUN)
< upper normal limit, left ventricular ejection fraction measured by
echocardiography 50%]; (9) age greater than 20 years and less
than 75 years; and (10) no prior treatment with taxanes.
Exclusion criteria included: (1) a known history of a hypersensi-
tive reaction to any drugs; (2) pregnancy and breast feeding; (3)
active concomitant malignancy; (4) unfavourable medical condi-
tions, such as uncontrolled infection, diabetes mellitus or cardiac
disease; (5) prior bone marrow transplantation; (6) a peripheral
neuropathy; (7) symptomatic brain metastases; and (8) hyper-
calcaemia (serum calcium > 12 mg dl-'). All patients gave written
informed consent before registration.
Drug administration and dose escalation procedures
Docetaxel and 5-FU were provided by Chugai Pharmaceutical,
Tokyo, Japan and Rhone-Poulenc Rorer. Docetaxel was supplied as
a concentrated sterile solution of40 mg ml-' in polysorbate 80. This
solution was diluted in 6 ml of 13% ethanol and then in 250 ml of
5% glucose and administered as a 1-h intravenous infusion on day
1. No premedication was performed for prevention ofallergic reac-
tion and emesis. 5-FU was diluted in 250-1000 ml per day of 5%
glucose and administered after docetaxel as a continuous 24-h
intravenous infusion on day 1 and then alone on days 2 to 5. Both
drugs were administered using an electric infusion pump.
The starting doses of docetaxel and 5-FU were 40 mg m-2 on
day I and 150 mg m- on days 1 to 5. Docetaxel/5-FU dose levels
were escalated as follows: 40/300, 50/300, 50/500, 60/500 and
60/750 mg m-2. We considered that dose-limiting toxicity (DLT)
had been achieved if patients experienced at least one of the
following: (1) grade 4 leucopenia or neutropenia lasting more than
5 days; (2) grade 2 fever lasting more than 3 days or sepsis proven
by blood culture with grade 4 leucopenia or neutropenia; (3) grade
4 thrombocytopenia and (4) greater than grade 3 non-haematolog-
ical toxicity. Intrapatient dose escalation was not allowed. It was
planned to enter three patients at each level and if DLT was
observed in one or two patients at one level, another three patients
were entered at this level. The maximum-tolerated dose (MTD)
was defined as the dosage that caused DLT in more than one half
of the patients during the first course. Toxicity was evaluated
according to Japan Clinical Oncology Group (JCOG) common
toxicity criteria (Tobinai et al, 1993). Patients continued to receive
their assigned treatment at the same dose level every 3-4 weeks,
provided that they did not develop progressive disease, refuse
further treatment or experience unacceptable toxicity. Patients
who experienced unacceptable toxicity in a prior course were
treated at a dosage-lowered level in the following courses.
Evaluation and response criteria
Before the first course, each patient was assessed by physical
examination, a complete medical history, chest radiography, bone
radiography, including skull, vertebra and pelvis, ultrasound ofthe
abdomen, computerized tomography ofthe brain, bone scintigram,
electrocardiogram, echocardiography and routine laboratory
studies; these consisted of a complete blood cell count, including
differential WBC count, electrolyte, BUN, creatinine, glucose,
total protein, serum albumin, calcium, alkaline phosphatase
(Al-p), lactate dehydrogenase (LDH), total bilirubin, alanine
aminotransferase (ALT), aspartate aminotransferase (AST) levels
and urinalysis. The complete blood cell counts were repeated at
Table 1 Patient characteristics
Total no. of patients
No. of assessable patients
Age (years)
Median (range)
Performance status
0
1
2
Advanced disease
Recurrent disease
No. of metastatic sites
2
>3
Site of disease
Breast
Skin
Lymph node
Bone
Visceral
Lung
Liver
Other viscera
Pleura/peritoneum
Prior chemotherapy
Anthracycline (+)
Anthracycline (-)
Adjuvant only
Metastatic disease only
Both adjuvant and metastatic
Radiation therapy (local)
19
18
55 (34-72)
8
8
2
6
12
3
6
9
2
1
10
12
6
7
1
4
15
3
4
6
8
6
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least three times per week after the start of treatment, and other
examinations were repeated twice a week. Evaluation of response
was required at each course. Response was evaluated according to
Japanese Breast Cancer Society criteria (Japanese Breast Cancer
Society, 1992). Complete response (CR) was defined as the disap-
pearance of all clinical evidence of active tumour with complete
reossification ofbone lesions and absence ofdisease-related symp-
tons for more than 4 weeks. Partial response (PR) was defined as
more than 50% reduction in the sum ofthe products oftwo perpen-
dicular diameters of all measurable lesions and remarkable reossi-
fication of osteolytic lesions without the appearance of new
lesions, or less than 25% increase of any lesion for more than 4
weeks. No change (NC) was defined as a < 50% reduction or
< 25% increase in the sum of the products of two perpendicular
diameters of all measurable lesions and no remarkable improve-
ment without the appearance of new lesions for at least 4 weeks
and no increase of bone lesions without the appearance of new
bone lesions for at least 8 weeks. Progressive disease (PD) was
defined as the unequivocal appearance of any new lesions or more
than 25% increase in the sum of perpendicular diameters of any
measured lesion.
Pharmacokinetic analysis
Heparinized blood samples (3 ml) for pharmacokinetic study were
obtained from the arm not used for drug infusion. Samples were
withdrawn at the following time points: before docetaxel infusion;
30 and 60 min after the start ofdocetaxel infusion; 15 and 30 min,
1, 2, 3, 4, 6 and 24 h after completion ofdocetaxel infusion on day
1, as well as before 5-FU infusion; 15 and 30 min, 1, 2, 3, 4, 6, 24,
48, 72, 96 and 120 h after the start of 5-FU infusion; and 15 and
30 min, 1, 2, 8 and 24 h after the completion of 5-FU infusion.
Each blood sample was centrifuged immediately and the plasma
Table 2 Results of treatment
No. of patients/
Level Taxoterea/5-FUb no. of courses Intolerablec
40/150 3/20 0
11 40/300 3/23 0
III 50/300 3/18 0
IV 50/500 3/19 0
V 60/500 6/27 3
amg m-2 on day 1. bmg m-2 on days 1 through 5. cNo. of cases who showed
dose-limiting toxicity.
was stored at -20°C until analysis. Docetaxel and 5-FU were
assayed by high-performance liquid chromatography with UV
detection (Jager et al, 1990; Vergniol et al, 1992). The detection
limits for docetaxel and 5-FU were 7.5 and 10 ng ml respectively.
The pharmacokinetic parameters of docetaxel were determined on
the basis of non-compartment analysis. Total clearance (CL) was
calculated by dividing the dose by the area under the concentration
vs time curve (AUC). Volume of distribution at steady-state (Vs,)
was estimated by the equation [CL x (mean residence time (MRT)
- (Infusion time (h)/2)]. The half-life time (t,,2) of docetaxel was
determined using the residual method. The AUC of docetaxel and
5-FU was calculated using the trapezoidal method. The AUC,
MRT andt,,,2were calculated using the computer program MULTI
(Yamaoka et al, 1981). In order to assess the pharmakokinetic and
pharmakodynamic relationships of docetaxel and 5-FU, the
percentage decrease in neutrophil count was calculated according
to the formula: percentage decrease = [(pretreatment count - nadir
count)/pretreatment count] x 100, and the relationships between
this parameter and the AUC of docetaxel or 5-FU were analysed
according to a sigmoid maximum effect(E1uax) model (Holford and
Table 3 Toxicity during the first course
Level I Level II Level IlIl Level IV Level V
Gradea Grade Grade Grade Grade
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Leucopenia 1 1 1 2 1 1 2 1 1 1 2 1 2
Neutropenia 1 1 2 1 1 1 1 1 1 3 3
Thrombocytopenia 1
Anaemia 1 2 2 3 1 1 4 1
Nausea and vomiting 2 1 2 1 1 2 3
Diarrhoea 1 1 1 2 1 1 1 1 1
Loss of appetite 1 1 1 1 1 3 1 1
Fatigue 2 1 1 4 1
Stomatitis 1 1 1 2
Fever 1 1 2 1 2 3
Skin rash 1 1
Total bilirubin
LDHb 1 2 3
Al-PC 1 1
Transaminases 2 1 1 5 1
Hypoalbuminaemia 1 1 2 1 2
Electrolyte imbalance 1 1 1 1
Vasculitis 1 1
Alopecia 2 3 3 3 4 1
Oedema (peripheral) 1 1
aJCOG toxicity criteria. bLactate dehydrogenase. cAlkaline phosphatase.
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Sheiner, 1982) as follows: percentage decrease in neutrophil
count = E,l,ax x (AUC)r/[(AUC90)' + (AUC)r].
The maximum effect (Emax), AUC () (the AUC that produces 50%
of the maximum effect) and r (sigmoidicity coefficient) were esti-
mated using non-linear least-squares regression using the computer
program Win Nonlin (Scientific Consulting, Apex, NC, USA).
To determine the correlation between dose and the AUC or peak
plasma concentrations (CQl,ax) of docetaxel and 5-FU, Pearson
correlation coefficients were calculated.
RESULTS
Patient characteristics
Nineteen patients were entered into this study from April to
November, 1995. One patient was ineligible, because she had
received two chemotherapy regimens after recurrence. Eighteen
patients were evaluable for toxicity and response.
Patient characteristics are listed in Table 1. The number of
patients and courses per dose level are listed in Table 2. The
number of treatment courses of docetaxel/5-FU ranged from one
to 13 (median, six; total, 107).
Toxicity during the first course
Haematological toxicity
One of the major toxicities observed with this regimen was
neutropenia (Table 3). One of three patients experienced grade 3
neutropenia at levels I, III and IV, while one ofthree patients expe-
rienced grade 4 neutropenia at levels III and IV. At level V, three of
six patients experienced grade 4 neutropenia. Among these, one
patient had grade 4 leucopenia, and neutropenia lasted for 5 days
with grade 2 diarrhoea and fever; she subsequently received gran-
ulocyte colony-stimulating factor (G-CSF) support. Among most
patients, neutrophil count reached its nadir on day 6 or 7 and
recovered to 2000 jt' by day 14. Mild anaemia was observed at
each level and seemed to be dose related. One of six patients at
level V experienced grade 3 anaemia.
Non-haematological toxicity
Gastrointestinal symptoms were the dominant non-haematological
toxicity, with severity appearing to be dose related (Table 3).
Diarrhoea was observed in one patient even at the lowest dose
level, more than grade 1 diarrhoea was observed in each patient at
dose levels I-IV. One of six patients at level V experienced grade
3 diarrhoea, which was observed on day 5 and was complicated
with grade 2 fever. She recovered from diarrhoea on day 10.
Another patient at the same level experienced grade 4 diarrhoea,
which was observed on day 6 and was accompanied by grade 2
fever on day 10. Diarrhoea was improved by day 16. There was no
relationship between the severity ofdiarrhoea and neutropenia. No
severe hypersensitive reactions were observed. However, transient
fever was observed on day 1 through 5 in two of 12 patients at
levels I-IV, which was considered to be due to an allergic reaction.
Only two patients at levels I and II had mild and transient oedema
during the first course. Elevations oftransaminases were observed
in 4 of 12 patients, which appeared to be dose related. Five of ten
patients with elevation of transaminases had liver metastases.
Onset of these abnormalities ranged from between day 1 and day
15 (median day 5). Among ten patients with hepatic toxicity, six
showed recovery within 14 days.
Toxicity observed after more than two courses
Cumulative toxicities were not severe in all 18 patients who
received more than two courses (Table 4). Anaemia seemed to be
related to the number of treatment courses. Neutropenia, gastro-
intestinal toxicities and elevation of transaminases were not
exacerbated by a greater number of treatment courses. Grade 1 or
2 elevation of transaminases was observed in 21 of 107 courses.
One patient with three courses at level I and another with six
courses at level III had grade 1 peripheral oedema. At level V, one
patient with two courses and another patient with three courses
had grade 1 and transient peripheral oedema. One patient treated
with more than two courses at level I and another with more than
nine courses at level II had mild and transient paraesthesia. Four of
18 patients who received more than two courses experienced grade
1 or 2 vasculitis. Dose reductions of one level were mandated in
the three of six patients at level V because ofgrade 3 diarrhoea or
grade 4 neutropenia during the first course.
Therapeutic efficacy
All patients had measurable disease. One patient with lymph node
metastases achieved CR and eight patients achieved PR (two
patients with lymph node metastases, two with lymph node and
Table 4 Toxicity of all courses
Level I Level II Level IlIl Level IV Level V
Gradea Grade Grade Grade Grade
1 or2 >3 1 or2 .3 1 or2 >3 1 or2 .3 1 or2 >3
Neutropenia 4 11 12 3 7 11 9 5 6 15
Thrombocytopenia 2 2
Anaemia 17 10 8 6 26 1
Diarrhoea 4 7 7 3 4 3
Stomatitis 4 3 1 4
Fever 3 2 2 11
Transaminases 3 3 3 5 11
Paresthesia 2 3
Vasculitis 2 1 1 1
Oedema (peripheral) 2 1 1 3
aJCOG toxicity criteria.
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Table 5 Therapeutic efficacy
Level Taxoterea/5-FUb Response
40/150x5 days 1 PR, 1 NC, 1 PD
11 40/300x5 days 2 PR, 1 PD
III 50/300x5 days 1 CR, 1 NC, 1 PD
IV 50/500x5 days 2 PR, 1 NC
V 60/500x5 days 3 PR, 1 NC, 2 PD
amg m-2 on day 1. bmg m-2 on days 1 to 5. CR, complete response; PR,
partial response; NC, no change; PD, progressive disease.
bone, two with liver, one with lung and liver, and one with bone).
The response rate was 50% (95% CI 26-74%) (Table 5). Seven of
nine patients who showed response in the present combination had
been treated with anthracycline-containing regimens previously.
Pharmacokinetics and pharmacodynamics
Plasma concentrations of docetaxel and 5-FU were quantitated in
18 and 17 patients, respectively, during the first course.
Pharmacokinetic parameters of docetaxel and 5-FU are summa-
rized in Table 6A and B. Mean plasma concentration-time profiles
are illustrated in Figure IA and B. Plasma disappearances of
docetaxel showed biphasic or triphasic profiles. The interpatient
variations in plasma concentrations of docetaxel and 5-FU were
large. Cmax and AUC of docetaxel were poorly related to the dose
of docetaxel (r= 0.08, P = 0.96, and 0.01, P = 0.77, respectively).
Cmax and AUC of 5-FU increased in proportion to the dose of
5-FU (r = 0.75, P < 0.01, and 0.81, P < 0.01, respectively). The
relationship between the AUC of docetaxel and the percentage
decrease in neutrophil count during the first course was
approximated using a sigmoid Emax model (Emax = 87.2+7.2%,
AUC50 = 874.8+95.3 ng h ml-1 and r = 3.3±1.5). But there was no
significant relation between the AUC of 5-FU and the percentage
decrease in neutrophil count. Scatterplots depicting the grade of
diarrhoea vs the AUC and Cmax of docetaxel and 5-FU during the
first course did not indicate a significant relation.
DISCUSSION
It is of cardinal importance to conduct clinical trials to evaluate
combination regimens including docetaxel to determine whether
they have enhanced anti-tumour efficacy. In the present study, we
chose continuous 5-FU infusion in combination with docetaxel to
evaluate clinical synergistic anti-tumour effects as a second-line
chemotherapy for advanced or recurrent breast cancer. We decided
to test docetaxel and 5-FU in doses of 40-60 mg m-2 and 150-
500 mg m-2 day-1 respectively.
In the Japanese phase II trials of docetaxel administered at
60 mg m-2 as a 1-h infusion every 3 or 4 weeks for previously
treated MBC, 61 of 71 patients (85.9%) and 56 of 66 (84.8%)
showed grade 3 and 4 neutropenia (Taguchi et al, 1994b; Adachi et
Table 6 Mean (± s.d.) pharmacokinetic parameters of docetaxel (A) and 5-FU (B) at the first course
A
Dose level No. of patients C. t/2(h)a AUC (0-=) CL V..
Docetaxel/5-FUx5 days (ng ml-') (ng h ml-') (mg m-2) (mg m-2)
(mg m-2)
40/150 3 1354.4 ±482.7 y= 10.9, 15.8 1801.3 810.3 25.0 9.5 95.2 ± 79.3
=0.7
40/300 3 1838.8 ± 830.8 y = 12.3 2316.0 + 1859.0 24.6 ± 13.7 33.8 ± 11.3
=4.0, 1.0
50/300 3 1222.4 ± 353.9 Y=25.1 1293.5 398.6 41.8+ 15.7 175.7± 241.5
= 1.3, 3.6
50/500 3 1462.3±369.0 y=5.6±1.6b 1599.1 ±441.8 33.2+ 10.4 51.2±30.2
60/500 6 1678.0 ± 376.4 y=20.0± 21.5b 2241.6 955.0 30.7+11.6 116.6 ± 170.6
f3 =2.3± 1.2*b
B
Dose level No. of patients Cmax AUC (O0
Docetaxel/5-FUx5days (ng ml-1) (ng h ml-')
(mg m-2)
40/150 3 66.1 ± 14.0 4613.0±879.1
40/300 3 143.9+ 19.8 9940.2 ± 3323.3
50/300 3 161.3 ±72.3 13603.5+ 5737.2
50/500 3 385.0 ±66.0 24633.4+ 7282.8
60/500 5 376.3± 218.2 26103.5 ± 9986.4
aTerminal half-life time. n- peak plasma concentration; AUC, area under concentration vs time clearaceLV vlume oldistrbutio aTerminal half-life time. b3. Cax peak plasma concentration; AUC, area under concentration vs time curve; CL, total , volume of distribution at
steady-state.
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Figure 1 (A) Mean plasma concentration curve of docetaxel. (B) Mean
plasma concentration curve of 5-FU
al, 1996). In the phase I trial of a single infusion of docetaxel as a
1-h infusion, two of six patients experienced grade 3 and 4
neutropenia at a dose of 50 mg m-2 and three of six experienced
grade 3 at a dose of60 mg m-2 (Ringel and Horwitz, 1991). Taking
the neutropenic profile of these trials of a single infusion of
docetaxel, combination of a 5-day continuous infusion of 5-FU
with docetaxel dose not seem to exacerbate neutropenia.
Severe diarrhoea was not frequently observed in a single 1-h
infusion ofdocetaxel phase II trials. In the Japanese phase II trials,
one of71 patients and one of66 patients showed grade 3 diarrhoea
(Taguchi et al, 1994b; Adachi et al, 1996). In the phase II trials of
docetaxel administered at 100 mg m-2, the frequencies of greater
than grade 2 diarrhoea were 7-15% (Chevallier et al, 1995; Valero
et al, 1995; Hudis et al 1996). On the other hand, it has been
reported that 5-FU frequently induces mild to moderate diarrhoea.
Frequency and severity of 5-FU-induced diarrhoea became much
less severe when given as a continuous infusion. In a study of
5-FU administered by a 5-day continuous infusion schedule for
patients with metastatic colorectal cancer, when 26 patients
received this treatment at doses ranging from 650 to 1300 mg m-2
day,-' grade 1 diarrhoea was observed in only one of a total of 185
courses (Milano et al, 1988). The diarrhoea observed in the present
combination, therefore, seems to be extraordinarily frequent and
severe. This excarbation may be the result of a possible drug-drug
interaction of docetaxel and 5-FU. Further investigation is needed
to elucidate the mechanism ofthis adverse synergy.
In the previous phase I and II trials of a 1-h infusion of
docetaxel, mild hepatic toxicity was observed in approximately
50% of the patients (Hudis et al, 1996); nor was this toxicity
remarkable in patients with 5-FU (Milano et al, 1988). The higher
incidence of hepatic toxicity observed in the present trial denotes
the need to clarify the interactions between these two agents at the
metabolic pathways.
In the previous studies of docetaxel administered as a single
infusion, it was reported that the AUC and the percentage decrease
in neutrophil count fitted well with a sigmoid Emax model (Bissett
et al, 1993; Extra et al, 1993). In the pharmacokinetic analysis of
the present combination of docetaxel and 5-FU, the AUC of
docetaxel correlated with the percentage decrease in neutrophil
count in this model. But a significant relationship between the
AUC of5-FU and the percentage decrease in neutrophil count was
not observed. These findings may indicate that docetaxel is the
principal contributor to neutropenia in the present combination.
And no remarkable relationship between pharmacokinetic parame-
ters ofdocetaxel or 5-FU and grade ofdiarrhoea were observed.
In this study, three of six patients showed DLTs (one with grade
4 neutropenia that lasted for 5 days and two with grade 3 and 4
diarrhoea). Therefore, we considered that the MTD was 60 mg m-2
ofdocetaxel on day 1 and 500 mg m-2 per day of5-day continuous
infusion of5-FU.
Seven of 15 patients who were previously treated with anthracy-
cline-containing chemotherapy achieved responses. This regimen
therefore seems to be active as a second-line chemotherapeutic
regimen against MBC. The activity of this regimen against MBC
should be evaluated further in a phase II trial.
In conclusion, 50 mg m-2 of docetaxel over 1 h on day I and
500 mg m-2 day-' ofcontinuous infusion of5-FU on days 1 to 5 at
3- or 4-week intervals is an appropriate schedule for future phase
II trials in patients previously treated for MBC. This combination
seems to be active as a second-line chemotherapeutic regimen
against MBC. Care should be taken to manage diarrhoea, which
may be adversely enhanced by this combination.
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